subscribeSubscribe
price-trendAsk Us
Curis Enters into Agreement for Emavusertib Combination Study in Melanoma

Curis Enters into Agreement for Emavusertib Combination Study in Melanoma
PR NEWSWIRE
05 Dec 2023
Share Share
FDA Lifts Partial Clinical Hold on TakeAim Leukemia Trial Emavusertib in AML/MDS

FDA Lifts Partial Clinical Hold on TakeAim Leukemia Trial Emavusertib in AML/MDS
ONCLIVE
07 Jul 2023
Share Share
FDA lifts partial hold on Curis` PhI/II leukemia study as biotech raises $15M 

FDA lifts partial hold on Curis` PhI/II leukemia study as biotech raises $15M 
Paul Schloesser ENDPTS
07 Jul 2023
Share Share
FDA puts Curis` leukemia trial on partial hold after patient death

FDA puts Curis` leukemia trial on partial hold after patient death
Nick Paul Taylor FIERCE BIOTECH
04 Apr 2023
Share Share
FDA lets biotech resume enrollment for part of phase 1/2 leukemia study

FDA lets biotech resume enrollment for part of phase 1/2 leukemia study
Gabrielle Masson FIERCEBIOTECH
31 Aug 2022
Share Share
FDA lifts partial clinical hold on Curis lymphoma study

FDA lifts partial clinical hold on Curis lymphoma study
Jim Cornall LABIOTECH
19 Aug 2022
Share Share
Curis Announces Encouraging Emavusertib Data at the 2022 ASCO

Curis Announces Encouraging Emavusertib Data at the 2022 ASCO
PRNEWSWIRE
04 Jun 2022
Share Share